The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo
| Autor: | Marilyn V. Zeman, Rachel F. Tyndale, Mirjana V. Djordjevic, Edward M. Sellers, Yamini Ramamoorthy |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
Male Nicotine Nitrosamines Metabolite Injections Subcutaneous Administration Oral Pharmacology Mixed Function Oxygenases Cytochrome P-450 CYP2A6 Placebos chemistry.chemical_compound In vivo medicine Humans CYP2A6 biology Chemistry Methoxsalen Smoking Public Health Environmental and Occupational Health Area under the curve Ganglionic Stimulants Enzyme inhibitor Area Under Curve biology.protein Carcinogens Female Aryl Hydrocarbon Hydroxylases Cotinine medicine.drug |
| Zdroj: | Nicotinetobacco research : official journal of the Society for Research on Nicotine and Tobacco. 5(6) |
| ISSN: | 1462-2203 |
| Popis: | Nicotine is metabolized to the inactive metabolite cotinine by cytochrome P450 2A6. NNK, or 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is a potent procarcinogen shown to be activated to a reactive mutagenic metabolite by the enzyme CYP2A6. We studied the effect of inhibiting CYP2A6 on smoking behavior and metabolism of the procarcinogen NNK. In study 1, abstinent smokers (n=7) received methoxsalen (a potent CYP2A6 inhibitor), 30-50 mg orally, one-half hour before three subcutaneous nicotine injections (31 microg/kg) were given at hourly intervals. Methoxsalen increased mean plasma nicotine by 47% (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|